Morepen Laboratories Ltd's Q4FY25 Quarter Results
- 13 May 2025
Result Summary
- Morepen Laboratories Ltd reported a 6.7% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4FY25). On a year-on-year (YoY) basis, it witnessed a growth of 16.5%.
- Its expenses for the quarter were down by 8.9% QoQ and up 8.3% YoY.
- The net profit increased 6.0% QoQ and increased 243.2% YoY.
- The earnings per share (EPS) of Morepen Laboratories Ltd stood at 0.5 during Q4FY25.
Financial Statments for Q4FY25
| (₹ crores) | Q4FY25 | Q3FY25 | Q4FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 427.32 | 458.12 | 366.81 | -6.7% | 16.5% |
Total Expenses | 385.11 | 422.91 | 355.67 | -8.9% | 8.3% |
Profit Before Tax | 42.20 | 35.21 | 11.14 | 19.9% | 278.8% |
Tax | 13.46 | 8.52 | 2.90 | 58.0% | 364.1% |
Profit After Tax | 28.28 | 26.69 | 8.24 | 6.0% | 243.2% |
Earnings Per Share | 0.50 | 0.50 | 0.20 | 0.0% | 150.0% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Morepen Laboratories Ltd is a well-established pharmaceutical company that operates in the healthcare sector. The company is known for its manufacturing and marketing of a wide range of pharmaceutical formulations, diagnostic products, and active pharmaceutical ingredients (APIs). Morepen Laboratories has been recognized for its commitment to innovation and quality in the healthcare industry. Recent developments include strategic expansions in their manufacturing capabilities and partnerships aimed at broadening their market reach. However, specific recent major developments are not available in the provided data.
Revenue
In Q4FY25, Morepen Laboratories Ltd reported a total income of ₹427.32 crores. This represents a decrease of 6.7% from the previous quarter, Q3FY25, when total income was ₹458.12 crores. However, on a year-over-year basis, there was a significant increase of 16.5% compared to Q4FY24, where the total income stood at ₹366.81 crores. This demonstrates variability in the company's revenue quarter-over-quarter while showing growth over the year. The financial data indicates fluctuations in income, with a notable rise in annual revenue from the previous year.
Profitability
The financial performance of Morepen Laboratories Ltd in terms of profitability shows a positive trend. The company recorded a profit before tax of ₹42.20 crores in Q4FY25, which is an increase of 19.9% from ₹35.21 crores in Q3FY25. Year-over-year, there was a substantial growth of 278.8% compared to the ₹11.14 crores reported in Q4FY24. Tax expenses for Q4FY25 were ₹13.46 crores, marking an increase of 58.0% quarter-over-quarter and 364.1% year-over-year. Profit after tax for Q4FY25 was ₹28.28 crores, showing a 6.0% increase from Q3FY25 and a 243.2% increase from Q4FY24. Earnings per share remained stable at ₹0.50 compared to the previous quarter, but showed a substantial increase of 150.0% from the previous year. These figures highlight significant profitability improvements on an annual basis.
Operating Metrics
The operating metrics for Morepen Laboratories Ltd reveal important data regarding expenses and efficiency. Total expenses in Q4FY25 amounted to ₹385.11 crores, which is a decline of 8.9% from ₹422.91 crores in Q3FY25. However, expenses increased by 8.3% when compared to ₹355.67 crores in Q4FY24. The reduction in expenses from the previous quarter suggests adjustments in operational activities. The financial data does not provide specific ratios like P/E ratio, debt-to-equity ratio, or current ratio. However, the trends in expenses and profitability figures provide insights into the company's operational performance and cost management strategies over the specified periods.